L. Kostanyan

Immunogenicity and safety of a second booster dose of an acellular pertussis vaccine combined with reduced antigen content diphtheria-tetanus toxoids 10 years after a first booster in adolescence: An open, phase III, non-randomized, multi-center study

Martina Kovac, Lusiné Kostanyan, N. Mesaros, 2018, Human vaccines & immunotherapeutics.

Respiratory Syncytial Virus Prefusion F Protein Vaccine in Older Adults.

M. Ison, J. Langley, L. Cámpora, 2023, The New England journal of medicine.

Impact of tetanus-diphtheria-acellular pertussis immunization during pregnancy on subsequent infant immunization seroresponses: follow-up from a large randomized placebo-controlled trial.

O. Vanderkooi, G. Zuccotti, F. Martinón-Torres, 2019, Vaccine.

Antibody persistence and safety and immunogenicity of a second booster dose nine years after a first booster vaccination with a reduced antigen diphtheria-tetanus-acellular pertussis vaccine (Tdap) in adults.

Lusiné Kostanyan, N. Mesaros, S. Kuriyakose, 2018, Vaccine.

Immunogenicity, transplacental transfer of pertussis antibodies and safety following pertussis immunization during pregnancy: Evidence from a randomized, placebo-controlled trial.

O. Vanderkooi, G. Zuccotti, F. Martinón-Torres, 2019, Vaccine.

Impact of maternal diphtheria-tetanus-acellular pertussis vaccination on pertussis booster immune responses in toddlers: Follow-up of a randomized trial.

O. Vanderkooi, G. Zuccotti, F. Martinón-Torres, 2021, Vaccine.

LB745. Respiratory Syncytial Virus (RSV) Prefusion F Protein Candidate Vaccine (RSVPreF3 OA) is Efficacious in Adults ≥ 60 Years of Age (YOA)

M. Ison, J. Langley, F. Martinón-Torres, 2022, Open Forum Infectious Diseases.